Table 2. Characteristics of included studies for direct meta-analysis.
| Lead author (y) | Study (phase) | Therapeutic regimen of TKI | Exon of EGFR mutationa | Sample size | Median PFS (m) | P-valueof PFS | HR19/21 of TKIb for PFS (95% CI) |
| Maemondo M (2010) | NEJ002 (III) | Gefitinib 250 mg/d, po | 19 | 58 | 11.5 | 0.90 | 0.939 (0.3518–2.5061) |
| 21 | 49 | 10.8 | |||||
| Asahina Hc (2006) | Prospective (II) | Gefitinib 250 mg/day, po | 19 | 13 | 8.3 | 0.678 | 1.410 (0.2785–7.1388) |
| 21 | 3 | 11.7 | |||||
| Jackman DMc (2006) | Retrospective | Gefitinib 250 mg/day, po or erlotinib 150 mg/day, po | 19 | 22 | 24 | 0.04 | 0.417 (0.1810–0.9608) |
| 21 | 10 | 10 | |||||
| Li JJ (2012) | Retrospective | Gefitinib 250 mg/day, po or erlotinib 150 mg/day, po | 19 | 33 | 9.0 | 0.002 | 0.778 (0.6635–0.9123) |
| 21 | 21 | 7.0 | |||||
| Lee VHF (2013) | Retrospective | Gefitinib 250 mg/day, po or erlotinib 150 mg/day, po | 19 | 64 | 12.8 | 0.040 | 0.649 (0.416–0.983) |
| 21 | 80 | 11.4 | |||||
| Lu RL (2014) | Retrospective | Gefitinib or erlotinib | 19 | 42 | 14.2 | <0.05d | 0.676 (0.4570–1.0000) |
| 21 | 34 | 9.6 | |||||
| Choi CM (2014) | Retrospective | Gefitinib 250 mg/day, po or erlotinib 150 mg/day, po | 19 | 77 | NA | NA | 0.846 (0.2815–2.5437) |
| 21 | 43 | NA |
a
Exon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.
b
HR19/21 of TKI represents HR19 exon deletion/exon 21 L858R mutation in TKI therapy cohort.
c
We considered time to progression (TTP) as PFS in studies of Asahina H and Jackman DM.
d
We considered P-value as 0.05 in Lu RL's study to calculate the HR19/21 of TKI for PFS and its 95% CI.
Abbreviations: CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; NA = not available; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.